{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:11:41Z","timestamp":1696932701632},"posted":{"date-parts":[[2023,10,9]]},"group-title":"In Review","reference-count":34,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Background: Herbicide and pesticide exposure (e.g., agent orange [AO]) is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).\u200b Monoclonal gammopathy of undetermined significance (MGUS) is the precursor state to MM; however, not all patients with MGUS progress to MM. It is unclear whether AO exposure increases the risk of progression of MGUS to MM.\nPurpose: We aimed to determine the association between AO exposure and progression to MM in a nation-wide study of U.S. Veterans with MGUS.\nPatients and Methods: This is a population-based cohort study of Vietnam Era Veterans diagnosed with MGUS. A natural language processing (NLP) algorithm was used to confirm MGUS and progression to MM. The association between AO and progression was analyzed using multivariable Fine-Gray subdistribution hazard model with death as a competing event. Veterans who served during the Vietnam War Era from 1\/9\/1962-5\/7\/1975 and were diagnosed with MGUS between 10\/1\/1999-12\/31\/2021 were included. We excluded patients with missing BMI values, progression within 1 year after MGUS diagnosis date, non-IgG or IgA MGUS, or birth years outside of the range of the AO exposed group, and race other than Black and White. AO exposure and service during 1\/9\/1962-5\/7\/1975 and stratified according to TCDD exposure levels by three time periods: 1\/9\/1962-11\/30\/1965 (high), 12\/1\/1965-12\/31\/1970 (medium), or 1\/1\/1971-5\/7\/1975 (low). The association between AO and progression was analyzed using multivariable Fine-Gray subdistribution hazard model with death as a competing event.\nResults: We identified 10,847 Veterans with MGUS, of whom 7,996 had AO exposure. Overall, 7.4% of MGUS patients progressed to MM over a median follow-up of 5.2 years. In multivariable analysis, AO exposure from 1\/9\/1962-11\/30\/1965, high TCDD exposure, was associated with an increased risk of progression (adjusted hazard ratio 1.48; 95% confidence interval 1.02-2.16), compared to Veterans with no exposure.\nConclusions: In patients with MGUS, the high Agent Orange exposure time period is associated with a 48% increased risk of progression to multiple myeloma. This suggests that patients with MGUS and prior Agent Orange exposure or occupational exposure to TCDD (eg. Agricultural workers) may require thorough screening for plasma cell dyscrasias.<\/jats:p>","DOI":"10.21203\/rs.3.rs-3396573\/v1","type":"posted-content","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:13:56Z","timestamp":1696868036000},"source":"Crossref","is-referenced-by-count":0,"title":["The Association of Agent Orange (AO) Exposure with Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Progression: A Population-based Study of Vietnam War Era Veterans"],"prefix":"10.21203","author":[{"given":"Lawrence W.","family":"Liu","sequence":"first","affiliation":[{"name":"St. Louis Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[{"name":"St. Louis Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Grandhi","sequence":"additional","affiliation":[{"name":"St. Louis Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Thomas","sequence":"additional","affiliation":[{"name":"St. Louis Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Vargo","sequence":"additional","affiliation":[{"name":"St. Louis Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen M.","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"St. Louis Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"St. Louis Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"issue":"23","key":"ref1","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar MV","year":"2016","unstructured":"Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016;128(23):2599\u20132606. doi:10.1182\/blood-2016-09-692954","journal-title":"Blood"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go RS","year":"2018","unstructured":"Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018;131(2):163\u2013173. doi:10.1182\/blood-2017-09-807560","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.014","author":"Therneau TM","year":"2012","unstructured":"Therneau TM, Kyle RA, Melton LJ, Larson DR, Benson JT, Colby CL, Dispenzieri A, Kumar S, Katzmann JA, Cerhan JR, Rajkumar SV. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012;87(11):1071\u20131079. doi:10.1016\/j.mayocp.2012.06.014"},{"issue":"3","key":"ref4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle RA","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine. 2018;378(3):241\u2013249. doi:10.1056\/NEJMoa1709974","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"ref5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle RA","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362\u20131369. doi:10.1056\/NEJMoa054494","journal-title":"N Engl J Med"},{"issue":"2","key":"ref6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.hoc.2012.02.009","article-title":"Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?","volume":"26","author":"Bianchi G","year":"2012","unstructured":"Bianchi G, Ghobrial IM. Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma? Hematol Oncol Clin North Am. 2012;26(2):383\u2013393. doi:10.1016\/j.hoc.2012.02.009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"ref7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.clml.2019.11.014","article-title":"Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit","volume":"20","author":"Bumma N","year":"2020","unstructured":"Bumma N, Nagasaka M, Hemingway G, Miyashita H, Chowdhury T, Kim S, Vankayala HM, Ahmed S, Jasti P. Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. Clin Lymphoma Myeloma Leuk. 2020;20(5):305\u2013311. doi:10.1016\/j.clml.2019.11.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"ref8","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1182\/blood.V126.23.4194.4194","article-title":"Correlated with Worse Outcome in Patients with Multiple Myeloma (MM)","volume":"126","author":"Previous Agent Orange Exposure Is","year":"2015","unstructured":"Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM). Blood. 2015;126(23):4194. doi:10.1182\/blood.V126.23.4194.4194","journal-title":"Blood"},{"issue":"8","key":"ref9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaoncol.2015.3015","article-title":"Association of Agent Orange With Plasma Cell Disorder: Further Evidence","volume":"1","author":"Munshi NC","year":"2015","unstructured":"Munshi NC. Association of Agent Orange With Plasma Cell Disorder: Further Evidence. JAMA Oncol. 2015;1(8):1035\u20131036. doi:10.1001\/jamaoncol.2015.3015","journal-title":"JAMA Oncol"},{"issue":"8","key":"ref10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jamaoncol.2015.2938","article-title":"Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study","volume":"1","author":"Landgren O","year":"2015","unstructured":"Landgren O, Shim YK, Michalek J, Costello R, Burton D, Ketchum N, Calvo KR, Caporaso N, Raveche E, Middleton D, Marti G, Vogt RF. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study. JAMA Oncol. 2015;1(8):1061\u20131068. doi:10.1001\/jamaoncol.2015.2938","journal-title":"JAMA Oncol"},{"issue":"6933","key":"ref11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nature01537","article-title":"The extent and patterns of usage of Agent Orange and other herbicides in Vietnam","volume":"422","author":"Stellman JM","year":"2003","unstructured":"Stellman JM, Stellman SD, Christian R, Weber T, Tomasallo C. The extent and patterns of usage of Agent Orange and other herbicides in Vietnam. Nature. 2003;422(6933):681\u2013687. doi:10.1038\/nature01537","journal-title":"Nature"},{"key":"ref12","author":"Ninth B","year":"2014","unstructured":"Update) C to R the HE in VV of E to H (Ninth B, Populations B on the H of S, Medicine I of. Exposure to the Herbicides Used in Vietnam. National Academies Press (US); 2014. Accessed February 24, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK195087\/"},{"issue":"3","key":"ref13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5271\/sjweh.782","article-title":"Occupation, pesticide exposure and risk of multiple myeloma","volume":"30","author":"Baris D","year":"2004","unstructured":"Baris D, Silverman DT, Brown LM, Swanson GM, Hayes RB, Schwartz AG, Liff JM, Schoenberg JB, Pottern LM, Greenberg RS, Stewart PA. Occupation, pesticide exposure and risk of multiple myeloma. Scand J Work Environ Health. 2004;30(3):215\u2013222. doi:10.5271\/sjweh.782","journal-title":"Scand J Work Environ Health"},{"issue":"2","key":"ref14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00053156","article-title":"Pesticide exposures and multiple myeloma in Iowa men","volume":"4","author":"Brown LM","year":"1993","unstructured":"Brown LM, Burmeister LF, Everett GD, Blair A. Pesticide exposures and multiple myeloma in Iowa men. Cancer Causes Control. 1993;4(2):153\u2013156. doi:10.1007\/BF00053156","journal-title":"Cancer Causes Control"},{"issue":"5","key":"ref15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/(sici)1097-0274(199711)32:5<510::aid-ajim11>3.0.co;2-5","article-title":"Meta-analyses of multiple myeloma and farming","volume":"32","author":"Khuder SA","year":"1997","unstructured":"Khuder SA, Mutgi AB. Meta-analyses of multiple myeloma and farming. Am J Ind Med. 1997;32(5):510\u2013516. doi:10.1002\/(sici)1097-0274(199711)32:5<510::aid-ajim11>3.0.co;2-5","journal-title":"Am J Ind Med"},{"issue":"25","key":"ref16","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study","volume":"113","author":"Landgren O","year":"2009","unstructured":"Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, Rajkumar SV, Alavanja MC. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113(25):6386\u20136391. doi:10.1182\/blood-2009-02-203471","journal-title":"Blood"},{"issue":"5","key":"ref17","doi-asserted-by":"publisher","first-page":"e4762","DOI":"10.7759\/cureus.4762","article-title":"Multiple Myeloma in an Agricultural Worker Exposed to Pesticides","volume":"11","author":"Packard E","year":"2019","unstructured":"Packard E, Shahid Z, Groff A, Patel R, Jain R. Multiple Myeloma in an Agricultural Worker Exposed to Pesticides. Cureus. 2019;11(5):e4762. doi:10.7759\/cureus.4762","journal-title":"Cureus"},{"key":"ref18","unstructured":"Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans. Accessed September 11, 2022. https:\/\/www.mdedge.com\/fedprac\/avaho\/article\/256893\/multiple-myeloma\/agent-orange-exposure-transformation-mgus-multiple"},{"key":"ref19","article-title":"Using natural language processing-assisted models to confirm MGUS diagnoses in Veterans\u2019 electronic health records","author":"Wang M","year":"2022","unstructured":"Wang M, Yu YC, Liu L, Schoen MW, Thomas TS, Colditz GA, Chang SH. Using natural language processing-assisted models to confirm MGUS diagnoses in Veterans\u2019 electronic health records. In:; 2022."},{"issue":"16_suppl","key":"ref20","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1200\/JCO.2022.40.16_suppl.1557","article-title":"Natural language processing of Veterans\u2019 electronic health records to confirm diagnoses of monoclonal gammopathy of undetermined significance","volume":"40","author":"Wang M","year":"2022","unstructured":"Wang M, Yu YC, Liu L, Schoen MW, Thomas TS, Colditz GA, Chang SH. Natural language processing of Veterans\u2019 electronic health records to confirm diagnoses of monoclonal gammopathy of undetermined significance. JCO. 2022;40(16_suppl):1557\u20131557. doi:10.1200\/JCO.2022.40.16_suppl.1557","journal-title":"JCO"},{"key":"ref21","author":"Wang Mei","unstructured":"Wang, Mei, Yu, YC, Liu, Lawrence, Schoen, Martin, Kumar, Akhil, Vargo, Kristin, Colditz, Graham, Thomas, Theodore, Chang, Su-Hsin. Developing Natural Language Processing-Assisted Classification Models to Confirm Diagnoses of MGUS and Progression in Veterans Health Administration Electronic Health Records. Manuscript submitted."},{"key":"ref22","author":"Wang Mei","year":"2023","unstructured":"Wang, Mei, Yu, YC, Liu, Lawrence, Schoen, Martin, Kumar, Akhil, Colditz, Graham, Thomas, Theodore, Chang, Su-Hsin. Using Natural Language Processing Pipeline to Extract Lab Results in Veteran Health Administration\u2019s Electronic Health Records. 5th Annual Institute of Clinical and Translational Sciences Symposium. Published online May 18, 2023. Accessed August 28, 2023. https:\/\/icts.wustl.edu\/37-using-natural-language-processing-pipeline-to-extract-lab-results-in-veteran-health-administrations-electronic-health-records\/"},{"key":"ref23","unstructured":"Exposure to Agent Orange in Vietnam - Public Health. Accessed February 24, 2023. https:\/\/www.publichealth.va.gov\/exposures\/agentorange\/locations\/vietnam.asp"},{"key":"ref24","author":"Lovis C","unstructured":"Lovis C, Payne TH. Extending the VA CPRS electronic patient record order entry system using natural language processing techniques. Proc AMIA Symp. Published online 2000:517\u2013521."},{"key":"ref25","author":"Payne TH","unstructured":"Payne TH. The transition to automated practitioner order entry in a teaching hospital: the VA Puget Sound experience. Proc AMIA Symp. Published online 1999:589\u2013593. Accessed September 21, 2023. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2232616\/"},{"key":"ref26","author":"Gonsoulin M","unstructured":"Gonsoulin M. VIReC Factbook Corporate Data Warehouse (CDW) Patient 3.1 Domain. Published online January 2018."},{"key":"ref27","unstructured":"Agent Orange exposure and VA disability compensation. Veterans Affairs. Published August 19, 2022. Accessed September 11, 2022. https:\/\/www.va.gov\/disability\/eligibility\/hazardous-materials-exposure\/agent-orange\/"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/hematology.2021000304","article-title":"Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies","volume":"2021","author":"Visram A","year":"2021","unstructured":"Visram A, Cook J, Warsame R. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematology. 2021;2021(1):673\u2013681. doi:10.1182\/hematology.2021000304","journal-title":"Hematology"},{"issue":"5","key":"ref29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/pds.5579","article-title":"Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System","volume":"32","author":"La J","year":"2023","unstructured":"La J, DuMontier C, Hassan H, Abdallah M, Edwards C, Verma K, Ferri G, Dharne M, Yildirim C, Corrigan J, Gaziano JM, Do NV, Brophy MT, Driver JA, Munshi NC, Fillmore NR. Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. Pharmacoepidemiology and Drug. 2023;32(5):558\u2013566. doi:10.1002\/pds.5579","journal-title":"Pharmacoepidemiology and Drug"},{"key":"ref30","unstructured":"The PACT Act And Your VA Benefits | Veterans Affairs. Accessed June 13, 2023. https:\/\/www.va.gov\/resources\/the-pact-act-and-your-va-benefits\/"},{"issue":"6","key":"ref31","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/archinte.158.6.626","article-title":"Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study","volume":"158","author":"Kazis LE","year":"1998","unstructured":"Kazis LE, Miller DR, Clark J, Skinner K, Lee A, Rogers W, Spiro A, Payne S, Fincke G, Selim A, Linzer M. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med. 1998;158(6):626\u2013632. doi:10.1001\/archinte.158.6.626","journal-title":"Arch Intern Med"},{"issue":"5 Pt 2","key":"ref32","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1475-6773.2005.00448.x","article-title":"Measurement in Veterans Affairs Health Services Research: veterans as a special population","volume":"40","author":"Morgan RO","year":"2005","unstructured":"Morgan RO, Teal CR, Reddy SG, Ford ME, Ashton CM. Measurement in Veterans Affairs Health Services Research: veterans as a special population. Health Serv Res. 2005;40(5 Pt 2):1573\u20131583. doi:10.1111\/j.1475-6773.2005.00448.x","journal-title":"Health Serv Res"},{"issue":"21","key":"ref33","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1001\/archinte.160.21.3252","article-title":"Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use","volume":"160","author":"Agha Z","year":"2000","unstructured":"Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160(21):3252\u20133257. doi:10.1001\/archinte.160.21.3252","journal-title":"Arch Intern Med"},{"key":"ref34","unstructured":"Supplemental Table 1. List of MM-specific treatments:"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3396573\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3396573\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:14:17Z","timestamp":1696868057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3396573\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":34,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3396573\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,10,9]]},"subtype":"preprint"}}